Status:

APPROVED_FOR_MARKETING

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Lead Sponsor:

MorphoSys AG

Collaborating Sponsors:

Clinigen Healthcare Ltd

Conditions:

DLBCL

Eligibility:

All Genders

18+ years

Brief Summary

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting th...

Detailed Description

This program is intended to provide access to patients with relapsed and/or refractory DLBCL who had at least one prior anti-CD20 containing regimen. Patients with primary refractory disease and doubl...

Eligibility Criteria

Inclusion

  • Major Inclusion Criteria :
  • Age ≥ 18 years
  • Patient able to provide written informed consent
  • Histologically-confirmed diagnosis of DLBCL, including transformation from an earlier diagnosis of indolent lymphoma.
  • Patients must have relapsed and/or refractory DLBCL, including primary refractory disease and double/triple hit status, after at least 1 prior anti-CD20 containing regimen.
  • Patients with a serious, life-threatening illness in which conventional therapies have failed, are unsuitable and/or are unavailable and participation in ongoing relevant clinical trials is not feasible.
  • Major Exclusion Criteria:
  • Patients who have other histological type of lymphoma, e.g. indolent Non-Hodgkin lymphoma (NHL), Primary mediastinal B-cell lymphoma (PMBL) or Burkitt Lymphoma
  • Patients who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period with lenalidomide
  • Patients with:
  • Known active bacterial and viral and fungal infections
  • Serology of chronic active viral Hepatitis B and/or C-Hepatitis
  • Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)
  • Patients who are unable to participate in the lenalidomide REMS program

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    EXPANDED_ACCESS

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT04300803

    Last Update

    August 28 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.